Lower Gastrointestinal Disorders

SECTION 1

Historical Context & Motivation

The study of lower gastrointestinal (GI) disorders has evolved dramatically over the past two centuries, driven by advances in endoscopy, histopathology, and molecular biology. Conditions such as inflammatory bowel disease, colorectal cancer, and diverticular disease represent a significant burden of morbidity and mortality worldwide, and understanding them is essential for any clinician preparing for the USMLE Step 2 examination. Early descriptions of bloody diarrhea and intestinal inflammation date to antiquity, but the systematic classification of these disorders required the development of modern surgical and pathological techniques. The recognition that many lower GI conditions share overlapping presentations—abdominal pain, altered bowel habits, and rectal bleeding—has driven the creation of structured diagnostic algorithms that remain the foundation of clinical reasoning today.

1859

Crohn's Disease Precursor Descriptions

Samuel Wilks described granulomatous inflammation of the terminal ileum, laying the groundwork for what Burrill Crohn would formally characterize decades later.

1932

Crohn, Ginzburg & Oppenheimer

Burrill Crohn and colleagues published their landmark paper describing 'regional ileitis,' distinguishing it from ulcerative colitis and establishing it as a separate clinical entity.

1958

Flexible Sigmoidoscopy Introduced

The advent of flexible endoscopy revolutionized the direct visualization of colonic mucosa, enabling biopsy-based diagnosis and transforming screening for colorectal neoplasia.

1994

APC Gene and Familial Adenomatous Polyposis

Identification of the adenomatous polyposis coli (APC) tumor suppressor gene solidified the adenoma-carcinoma sequence model and ushered in molecular genetics for colorectal cancer screening.

2010s

Biologic Therapies & Microbiome Research

TNF-α inhibitors, integrin blockers, and fecal microbiota transplantation transformed management of IBD and recurrent Clostridioides difficile infection, reflecting a paradigm shift toward targeted immunomodulation.

The central clinical question that this lesson addresses is: given a patient with lower abdominal pain, diarrhea, rectal bleeding, or altered bowel habits, how does the clinician systematically differentiate among the major lower GI disorders, initiate appropriate diagnostic workup, and select evidence-based treatment? Mastering this framework is indispensable for USMLE Step 2, where vignette-based questions demand rapid pattern recognition and structured clinical reasoning.

SECTION 2

Core Principles & Definitions

Lower GI disorders encompass pathology from the ligament of Treitz distally through the anal canal. For the purposes of Step 2 preparation, the most high-yield conditions cluster into several major categories: inflammatory bowel disease (IBD), colorectal neoplasia, diverticular disease, infectious colitis, and functional bowel disorders. Understanding the distinguishing features within and between these categories is the foundation upon which clinical management decisions are built.

Inflammatory Bowel Disease

Chronic, relapsing immune-mediated inflammation. Crohn disease involves transmural, skip lesions anywhere from mouth to anus; ulcerative colitis is limited to continuous mucosal inflammation of the colon beginning at the rectum.

Colorectal Neoplasia

Encompasses the adenoma-carcinoma sequence driven by APC, KRAS, and p53 mutations, hereditary syndromes (FAP, Lynch syndrome), and sporadic colorectal cancer—the third leading cause of cancer death in the United States.

Diverticular Disease

Outpouchings of the colonic mucosa and submucosa through the muscularis at points of vasa recta penetration. Diverticulosis is typically asymptomatic; diverticulitis presents with LLQ pain, fever, and leukocytosis.

Infectious & Ischemic Colitis

Includes C. difficile colitis (antibiotic-associated pseudomembranous colitis), bacterial dysentery (Shigella, EHEC), and ischemic colitis at watershed areas such as the splenic flexure.

Functional Bowel Disorders

Irritable bowel syndrome (IBS) is a diagnosis of exclusion defined by Rome IV criteria—recurrent abdominal pain associated with defecation or a change in stool frequency or form, without identifiable structural pathology.

✦ KEY TAKEAWAY

Think of the lower GI tract as a highway system: IBD is like chronic road damage that keeps recurring despite repairs; colorectal cancer is a construction project that grows unchecked from a small pothole (adenoma) into a massive obstruction (carcinoma); diverticulitis is a blowout in a structurally weakened tire wall; and IBS is a traffic jam with no identifiable accident—the road looks fine, but the flow is disordered. Recognizing which 'road problem' you are dealing with guides every subsequent management decision.

SECTION 3

Visual Explanation — IBD: Crohn Disease vs. Ulcerative Colitis

This side-by-side comparison highlights the key distinguishing features between Crohn disease (left, violet) and ulcerative colitis (right, pink). Note the differences in location, depth of inflammation, histological findings, serological markers, complications, and surgical curability. These distinctions are heavily tested on USMLE Step 2.

The diagram above encapsulates the fundamental contrast tested on board examinations. Crohn disease classically affects the terminal ileum with transmural inflammation that produces non-caseating granulomas, fistulae, and strictures, while ulcerative colitis remains confined to the colon with continuous mucosal inflammation extending proximally from the rectum. The serological markers—ASCA (anti-Saccharomyces cerevisiae antibodies) for Crohn disease and p-ANCA (perinuclear antineutrophil cytoplasmic antibodies) for ulcerative colitis—serve as adjunctive tools but are not individually diagnostic. Perhaps the most critical distinction for management is that total proctocolectomy is curative for UC but Crohn disease recurs after resection, making medical therapy the cornerstone of Crohn management.

SECTION 4

Pathophysiology & Mechanisms

Inflammatory Bowel Disease — Immune Dysregulation

The pathogenesis of IBD involves a dysregulated mucosal immune response to commensal gut flora in genetically susceptible individuals. In Crohn disease, Th1 and Th17 cell responses dominate, mediated by cytokines including TNF-α, IL-12, and IL-23; transmural inflammation leads to granuloma formation, fibrosis, and fistula development. In ulcerative colitis, a Th2-mediated response with IL-5 and IL-13 drives superficial mucosal inflammation and crypt destruction. Genetic susceptibility loci include NOD2/CARD15 for Crohn disease and HLA-DRB1 associations for UC. Environmental triggers—smoking (protective in UC, detrimental in Crohn), NSAIDs, stress, and prior infections—modulate disease expression.

Adenoma-Carcinoma Sequence

Colorectal cancer develops through a well-characterized molecular progression. The chromosomal instability (CIN) pathway accounts for approximately 85% of sporadic colorectal cancers. It begins with inactivation of the APC tumor suppressor gene (chromosome 5q), which leads to adenoma formation. Subsequent KRAS oncogene activation (chromosome 12p) promotes adenoma growth, followed by p53 loss (chromosome 17p) and DCC/SMAD4 loss (chromosome 18q), which together drive the transition to carcinoma. The microsatellite instability (MSI) pathway accounts for approximately 15% of cases and arises from defective DNA mismatch repair (MLH1, MSH2, MSH6, PMS2), either sporadically via MLH1 promoter hypermethylation or hereditarily in Lynch syndrome.

Diverticular Disease Pathophysiology

Colonic diverticula are false (pseudo) diverticula consisting of mucosal and submucosal herniation through the muscularis propria at sites of nutrient artery (vasa recta) penetration. The sigmoid colon is most commonly affected due to its narrower diameter and consequently higher intraluminal pressure, as described by Laplace's law. Diverticulitis occurs when a fecalith obstructs the diverticular neck, leading to bacterial proliferation, micro-perforation, and pericolonic inflammation. Complications include abscess, free perforation, fistula formation (colovesical fistulae presenting with pneumaturia), and stricture.

LAPLACE'S LAW (WALL TENSION)

T = P × r / (2 × w)

Where T = wall tension, P = intraluminal pressure, r = radius of the lumen, and w = wall thickness. As the sigmoid colon has the smallest radius in the large intestine, it generates the highest intraluminal pressures during segmental contractions, explaining why diverticula form preferentially in this region.

SECTION 5

Classification & Diagnostic Approach

Algorithmic approach to lower GI bleeding. The first priority is always hemodynamic stabilization. In stable patients, colonoscopy within 24 hours is the diagnostic and therapeutic modality of choice. In actively bleeding, unstable patients, CT angiography or conventional angiography allows localization and potential embolization. Surgery is reserved for refractory cases. Note the reminder to exclude an upper GI source with nasogastric aspirate.

Differential Diagnosis by Presentation Pattern

High-yield presentation patterns and their differential diagnoses for USMLE Step 2.

Presentation	Key Differential Diagnoses	Initial Workup
Bloody diarrhea	UC, infectious colitis (EHEC, Shigella, C. diff), ischemic colitis, Crohn colitis	Stool studies (culture, C. diff toxin, ova & parasites), CBC, CRP/ESR, colonoscopy with biopsy
LLQ pain + fever	Acute diverticulitis, perforated sigmoid cancer, IBD flare	CT abdomen/pelvis with IV contrast (avoid colonoscopy in acute diverticulitis), CBC with differential, CRP
Change in bowel habits + weight loss	Colorectal cancer, IBD, celiac disease, chronic mesenteric ischemia	Colonoscopy, CBC (iron deficiency anemia), CEA, CT abdomen if mass suspected
Painless hematochezia	Diverticular bleeding, AVM/angiodysplasia, hemorrhoids, colorectal polyps/cancer	Colonoscopy, tagged RBC scan or CTA if brisk bleeding, anoscopy for anorectal sources
Chronic abdominal pain, no alarm features	IBS, functional dyspepsia, lactose intolerance, celiac disease	Rome IV criteria assessment, CBC, CRP, fecal calprotectin, tissue transglutaminase IgA, consider colonoscopy if age >45 or alarm features

SECTION 6

Worked Example — Clinical Vignette

Vignette: A 28-year-old woman presents with 6 weeks of bloody diarrhea (8–10 stools/day), lower abdominal cramping, tenesmus, and a 4-kg unintentional weight loss. She has no history of travel, recent antibiotic use, or NSAID use. Physical examination reveals diffuse abdominal tenderness greatest in the left lower quadrant without peritoneal signs. Vital signs show temperature 38.2°C, heart rate 102 bpm, and blood pressure 118/72 mmHg. Laboratory studies show hemoglobin 10.2 g/dL, WBC 12,400/μL, CRP 68 mg/L, and albumin 3.0 g/dL. Stool studies for C. difficile toxin, enteric culture, and ova and parasites are negative. Colonoscopy reveals continuous erythematous, friable, and ulcerated mucosa extending from the rectum to the splenic flexure with pseudopolyps; the terminal ileum appears normal.

Step-by-Step Clinical Reasoning

Step 1 — Identify the Presentation PatternThe hallmark features here are bloody diarrhea with tenesmus in a young patient, combined with weight loss and anemia. This immediately places the presentation in the category of inflammatory colitis. The absence of recent antibiotics makes C. difficile less likely, and negative stool studies exclude common infectious etiologies.

Pattern: Chronic inflammatory bloody diarrhea

Step 2 — Narrow the DifferentialThe colonoscopy findings are critical: continuous mucosal inflammation extending from the rectum proximally with pseudopolyps, and a normal terminal ileum. Continuous involvement starting at the rectum is the hallmark of ulcerative colitis, whereas Crohn disease would present with skip lesions, potentially with ileal involvement. Ischemic colitis typically affects the watershed area (splenic flexure) in elderly or hypotensive patients, not a 28-year-old. The absence of granulomas, fistulae, or transmural disease further supports UC.

Diagnosis: Ulcerative colitis (extensive colitis — Montreal E3)

Step 3 — Assess Disease SeverityUsing the Truelove and Witts criteria: >6 bloody stools/day, temperature >37.8°C, heart rate >90 bpm, hemoglobin <10.5 g/dL, and ESR/CRP elevated. This patient meets criteria for moderate-to-severe ulcerative colitis. The low albumin (3.0 g/dL) further suggests significant systemic inflammation and possible protein-losing enteropathy.

Severity: Moderate-to-severe UC flare

Step 4 — Initiate Appropriate ManagementFor moderate-to-severe UC, initial management includes intravenous corticosteroids (e.g., methylprednisolone 60 mg/day IV). If there is no response within 3–5 days, rescue therapy with infliximab or cyclosporine should be considered. Simultaneously, begin screening for latent tuberculosis (given potential biologic use), check hepatitis B serologies, and ensure vaccinations are up to date. Maintenance therapy after remission induction will involve a steroid-sparing agent such as a thiopurine (azathioprine), anti-TNF biologic (infliximab, adalimumab), or vedolizumab. 5-ASA agents (mesalamine) are appropriate for mild-to-moderate UC but are typically insufficient for this severity.

Management: IV corticosteroids → steroid-sparing maintenance → consider rescue biologic if refractory

Step 5 — Address Complications & SurveillanceMonitor for toxic megacolon (colonic dilation >6 cm on abdominal X-ray with systemic toxicity—this is a surgical emergency requiring colectomy). Long-term, this patient has increased risk of colorectal cancer; surveillance colonoscopy should begin 8–10 years after diagnosis for extensive colitis, with biopsies taken every 1–2 years. Extraintestinal manifestations to screen for include primary sclerosing cholangitis (obtain liver function tests, consider MRCP if alkaline phosphatase elevated), pyoderma gangrenosum, erythema nodosum, and uveitis.

Key: Monitor for toxic megacolon acutely; CRC surveillance colonoscopy starting 8–10 years after diagnosis

SECTION 7

Treatment Strategies — Comparison & Limitations

Major drug classes used in IBD management with key board-relevant side effects.

Medication Class	Examples	Indications	Key Side Effects / Limitations
5-ASA agents	Mesalamine, sulfasalazine, balsalazide	Mild-moderate UC (induction & maintenance); limited role in Crohn	Interstitial nephritis (rare), headache, diarrhea; sulfasalazine causes folate deficiency
Corticosteroids	Prednisone, methylprednisolone, budesonide	Acute flares of IBD (induction only); NOT for maintenance	Osteoporosis, adrenal suppression, hyperglycemia, infection risk; steroid dependence
Thiopurines	Azathioprine, 6-mercaptopurine	Steroid-sparing maintenance in IBD	Myelosuppression (check TPMT before use), pancreatitis, hepatotoxicity, lymphoma risk
Anti-TNF agents	Infliximab, adalimumab, certolizumab	Moderate-severe IBD, fistulizing Crohn	Screen for TB/HBV before starting; infusion reactions, serious infections, demyelination, heart failure exacerbation
Integrin inhibitors	Vedolizumab (α₄β₇)	Moderate-severe IBD, gut-selective (lower systemic immunosuppression)	Slow onset of action (8–14 weeks); nasopharyngitis, headache; does NOT increase PML risk (unlike natalizumab)

✦ KEY TAKEAWAY

The treatment paradigm for IBD follows a step-up or top-down approach depending on disease severity. Think of it like managing a fire: a small campfire (mild disease) needs a bucket of water (5-ASA), a house fire (moderate disease) needs a fire engine (steroids for induction, then immunomodulators), and a wildfire (severe/refractory disease) needs aerial support (biologics). The critical rule for boards: corticosteroids are never appropriate for maintenance therapy—always transition to a steroid-sparing agent.

SECTION 8

Colorectal Cancer Screening & Hereditary Syndromes

Colorectal cancer screening is a high-yield USMLE topic that bridges preventive medicine and gastroenterology. The current USPSTF recommendation (2021) is to begin average-risk screening at age 45 years, a change from the prior recommendation of 50, driven by rising incidence of early-onset colorectal cancer. Screening options include colonoscopy every 10 years, annual FIT (fecal immunochemical test), FIT-DNA (Cologuard) every 1–3 years, or CT colonography every 5 years. Any positive non-invasive test requires follow-up colonoscopy. For patients with a first-degree relative diagnosed with CRC before age 60, screening should begin at age 40 or 10 years before the age of the youngest affected relative, whichever is earlier.

Hereditary colorectal cancer syndromes with genetics, features, and surveillance recommendations.

Syndrome	Genetics	Key Features	Surveillance / Management
FAP	APC gene (autosomal dominant); >100 adenomatous polyps	100% CRC risk by age 40 without treatment; congenital hypertrophy of retinal pigment epithelium; Gardner syndrome variant (desmoid tumors, osteomas)	Sigmoidoscopy starting age 10–12; prophylactic total proctocolectomy recommended by late teens/early 20s
Lynch Syndrome (HNPCC)	Mismatch repair genes (MLH1, MSH2, MSH6, PMS2); autosomal dominant; microsatellite instability	Right-sided CRC, ~80% lifetime CRC risk; associated endometrial, ovarian, gastric, urologic cancers; Amsterdam II criteria or Bethesda guidelines for identification	Colonoscopy every 1–2 years starting age 20–25; consider screening for associated cancers
Peutz-Jeghers	STK11/LKB1 (autosomal dominant); hamartomatous polyps	Mucocutaneous hyperpigmentation (lips, buccal mucosa, hands); increased risk of GI, breast, pancreatic, gynecologic cancers; intussusception from polyps	Upper and lower endoscopy starting in late teens; comprehensive cancer surveillance
Juvenile Polyposis	SMAD4 or BMPR1A (autosomal dominant); juvenile/hamartomatous polyps	Rectal bleeding and anemia in children/adolescents; increased CRC risk (9–50% lifetime)	Colonoscopy beginning age 12–15; upper endoscopy from age 12

🎯 High-Yield Board Pearl

Lynch syndrome is the most common hereditary colorectal cancer syndrome. Remember the mnemonic for Amsterdam II criteria: 3-2-1 — at least 3 family members with HNPCC-associated cancer, across 2 generations, with at least 1 case before age 50. All CRC tumors should be tested for MSI or by immunohistochemistry for mismatch repair proteins to identify potential Lynch syndrome patients.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A 35-year-old man with a 5-year history of ulcerative colitis limited to the rectum (proctitis) asks about his colorectal cancer risk. Compared to a patient with pancolitis diagnosed at the same age, how does his cancer risk differ, and when should surveillance colonoscopy begin for each?

PROBLEM 2 — BASIC CALCULATION

A 72-year-old woman presents with acute-onset painless hematochezia. She is hemodynamically stable. Her hemoglobin is 9.8 g/dL (baseline 13.2 g/dL). What is the most likely diagnosis, and what is the recommended initial diagnostic test?

PROBLEM 3 — INTERMEDIATE

A 60-year-old man with a history of recurrent episodes of left lower quadrant abdominal pain presents with fever (38.9°C), LLQ tenderness with localized peritoneal signs, and leukocytosis (WBC 16,200/μL). CT of the abdomen and pelvis reveals sigmoid diverticulitis with a 4-cm pericolic abscess. What is the most appropriate management?

PROBLEM 4 — APPLIED

A 22-year-old woman with known Crohn disease affecting the terminal ileum presents with a painful, draining perianal fistula. She is currently on mesalamine. Her disease is otherwise moderate in severity with intermittent flares requiring short courses of prednisone 2–3 times per year. She has not been on immunomodulators or biologics. What changes to her treatment plan are most appropriate?

PROBLEM 5 — CRITICAL THINKING

A 45-year-old man undergoes colonoscopy for screening. Biopsy of a right-sided sessile polyp reveals a 2.5-cm tubulovillous adenoma with high-grade dysplasia. Immunohistochemistry shows loss of MSH2 and MSH6 expression. He has no personal history of cancer. Family history reveals his father was diagnosed with colon cancer at age 48 and a paternal aunt had endometrial cancer at age 52. What is the most likely unifying diagnosis, what additional testing is warranted, and how should his family be counseled?

SUMMARY

Summary — Lower Gastrointestinal Disorders

Lower gastrointestinal disorders represent a high-yield category for USMLE Step 2 that demands systematic clinical reasoning. Inflammatory bowel disease is divided into Crohn disease (transmural, skip lesions, granulomas, fistulae, ASCA-positive) and ulcerative colitis (mucosal, continuous from rectum, pseudopolyps, p-ANCA-positive, curable by proctocolectomy). Treatment follows a step-up or top-down approach from 5-ASA agents through immunomodulators to biologics, with the cardinal rule that corticosteroids are never used for maintenance. Colorectal cancer develops via the adenoma-carcinoma sequence (APC → KRAS → p53) or the microsatellite instability pathway. Screen average-risk individuals starting at age 45. Hereditary syndromes—FAP (APC, prophylactic colectomy), Lynch syndrome (MMR genes, 3-2-1 Amsterdam criteria), and Peutz-Jeghers (STK11, mucocutaneous pigmentation)—require early and aggressive surveillance.

Diverticular disease is managed based on the presence or absence of complications: uncomplicated diverticulitis responds to antibiotics and bowel rest, while complicated cases (abscess ≥3 cm, perforation, fistula, obstruction) require percutaneous drainage or surgery. Lower GI bleeding demands hemodynamic stabilization first, followed by colonoscopy in stable patients or CT angiography/embolization in actively bleeding unstable patients. Finally, irritable bowel syndrome remains a diagnosis of exclusion defined by Rome IV criteria; ensure alarm features (weight loss, anemia, rectal bleeding, family history of CRC, onset after age 50) are absent before assigning this diagnosis. Mastery of these conditions—their distinguishing features, diagnostic algorithms, and management principles—provides a robust framework for tackling board-style clinical vignettes.